# Cyterix Pharmaceutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cyterix-pharmaceutics

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.cyterix.com
- Total disclosed funding: $9.2M
- Latest round: Series A (Jun 7, 2011)
- Investors on record: 2

## About

Cyterix Pharmaceutics is a biotechnology firm focused on developing innovative therapeutics to address unmet medical needs in oncology. The company leverages advanced scientific research to create effective treatments for cancer patients.Founded in 2010 and headquartered in San Francisco, US, Cyterix Pharmaceutics specializes in oncology therapeutics. The company has engaged in 4 deals, with its most recent funding round occurring on July 1, 2012, where it raised USD 7.29 mn from SV Health Investors. The company remains independent and has not undergone significant changes in its operational strategy since its inception.Cyterix Pharmaceutics focuses on developing proprietary drug candidates aimed at treating specific cancer types. Their products are designed to target and inhibit cancer cell growth, providing patients with potential new options in their treatment regimens. The firm markets its solutions primarily in North America and is expanding its research capabilities to cater to global markets, addressing diverse patient needs across various regions.The revenue model of Cyterix Pharmaceutics is primarily based on funding through investments that support their drug development initiatives. The company generates revenue from grants and investments intended for advancing its clinical trials and research projects, ensuring sustained growth and development within the biotech sector.Cyterix Pharmaceutics aims to launch new drug candidates within the next 18 months, focusing on expanding its portfolio of oncology treatments. Following the recent funding round of USD 7.29 mn in July 2012, the company plans to allocate these resources towards accelerating clinical trials and enhancing research capabilities. Additionally, Cyterix is targeting expansion into European and Asia-Pacific markets by 2015, seeking to establish partnerships with local healthcare providers and researchers to enhance its global reach.

## Funding rounds

- Series A, Jun 7, 2011, $9.2M — SV Health Investors, The Column Group

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A